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Abstract
Granulocyte macrophage-colony stimulating factor (GM-CSF) increases ovine interferon-tau (oIFN)
secretion by ovine conceptuses, but endometrial production of GM-CSF has not been characterized.
Endometrial GM-CSF expression was evaluated in ovariectomized ewes implanted with estradiol-17
(E2) and/or progesterone (P4) for 14 days, in day 14 cyclic and day 14 pregnant ewes. Relative levels of
endometrial GM-CSF mRNA were 3-fold higher in E2- and E2/P4-treated ewes than that of control or
P4-treated ovariectomized ewes. Levels of endometrial GM-CSF mRNA for cyclic ewes were similar
to E2- and E2/P4-treated ewes, but amounts of GM-CSF mRNA in pregnant ewes were 2-fold higher.
GM-CSF concentrations in endometrial culture media, determined by GM-CSF bioassay, for cyclic
and E2/P4-treated ovariectomized ewes were 3-fold higher than those of control, E2- and P4-treated
ovariectomized ewes; however, amounts of GM-CSF in pregnant ewes were 2-fold higher. Immunore-
active GM-CSF, examined by western blot, was detected in the culture medium from E2/P4-treated
ovariectomized, cyclic and pregnant ewes. Luminal and glandular epithelia and stromal regions were
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determined to be sites of GM-CSF expression by immunohistochemistry and in situ hybridization tech-
niques. Data indicate that combined E2 and P4 treatment of ovariectomized ewes is sufficient to restore
GM-CSF expression to the level found in cyclic ewes; however, GM-CSF mRNA and protein in preg-
nant ewes is 2-fold greater than in ovariectomized or cyclic ewes. These data suggest that the conceptus,
in addition to steroids, may play a role in the regulation of endometrial production of GM-CSF.
Published by Elsevier Science Inc.
1. Introduction
Ovine interferon-tau (oIFN) is a conceptus signal that is implicated in the process of
maternal recognition of pregnancy [1–4]. Accumulating data shows that oIFN production
by the conceptus of ruminant ungulates is positively regulated by endometrially derived cy-
tokine/growth factors [5,6]. One of these factors, granulocyte macrophage-colony stimulating
factor (GM-CSF) [7], increases conceptus production of oIFN in vitro [8,9]. GM-CSF mRNA
has been localized by in situ hybridization to luminal and glandular epithelia of the ovine uterus
on day 14–16 of gestation [8]. In order for GM-CSF to manifest an effect on conceptus pro-
duction of oIFN, GM-CSF needs to be available for the conceptus in utero. The production
of this protein in utero has not been well characterized.
GM-CSF production has been extensively studied in hematopoietic cells. Activation of
T-cells by recognition of antigens on antigen responding cells leads to rapid induction of a
nuclear protooncogene, c-fos, followed by induction of a battery of lymphokine genes in-
cluding interleukin-2 and GM-CSF [10,11]. Major events associated with T-cell activation
that upregulate GM-CSF production are the activation of protein kinase C second messenger
system and increased concentrations of free intracellular calcium [12,13]. This stimulation
of GM-CSF levels appears to be the result of increased transcription, as the promoter region
of GM-CSF contains two cis-acting elements, GM-B/GC-box and conserved lymphokine
element O (CLEO), that are required for maximal induction of the GM-CSF gene follow-
ing stimulation with phorbol-12-myristate-13-acetate (PMA) or calcium ionophore (A23187)
[14]. In addition, uterine epithelial cells were found to be another source of GM-CSF expres-
sion [15,16]. However, GM-CSF expression in cell types other than T-cells and an endocrine
or paracrine factors(s) that directly regulates endometrial GM-CSF production have not been
well characterized.
The steroid regulation of GM-CSF production from the ovine uterine endometrium has not
been investigated. Ovine GM-CSF (oGM-CSF) production from the endometrium may be
regulated partially by steroid hormones as demonstrated by Robertson et al. [16,17] when
uterine epithelial production of GM-CSF was increased in ovariectomized mice by exoge-
nous estrogens. Because estrogens elicit considerable uterine edema [18] and alter the cel-
lular composition of the uterus [19], in situ techniques are required to determine the uterine
source of growth factors/cytokines; resident endometrial cells, cells recruited to synthesize
specific growth factors/cytokines and/or the influx of serum growth factors into the uterus.
To ascertain endometrial production of GM-CSF, in addition to the presence of GM-CSF
in uterine flushing medium, endometrial tissues need to be cultured in vitro and the culture
media must be examined for the presence of GM-CSF. Therefore, using endometrial culture,
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immunohistochemistry and in situ hybridization methods, this study was undertaken to (1)
determine the effects of estradiol-17 (E2) and/or progesterone (P4) on the expression of en-
dometrial GM-CSF in ovariectomized ewes, and (2) characterize endometrial expression of
GM-CSF in cyclic and pregnant ewes. A newly developed antibody against oGM-CSF was
used to detect and neutralize endometrial GM-CSF.
2. Materials and methods
2.1. Animals
Thirty mature, whiteface crossbred ewes were maintained in drylot pens and assigned to three
experimental groups: (I) ovariectomized (n = 15), (II) day 14 cyclic (n = 7), and (III) day 14
pregnant (n = 8) ewes. Estrus was synchronized in all ewes using a 14-day treatment with an
intravaginal sponge containing 40 mg of 17-acetoxy-9-fluoro-11-hydroxy P4. On the day
of sponge removal, ewes were given an intramuscular injection of 10 mg P4. The following day,
a second intramuscular injection of 10 mg P4 and a single subcutaneous injection of 500 IU
PMSG were administered [6].
On day 14 after the synchronized estrus (day 0 = day of estrus), 12 group I ewes were
anesthetized with xylazine hydrochloride (0.1 mg/lb) and lidocaine [6] and both ovaries were
removed through a midventral laparotomy. After a 4-week recovery, ovariectomized ewes
were aseptically implanted subcutaneously with the following treatments: control-blank silas-
tic implants (n = 3), two E2 silastic implants (n = 3), three P4 elastomer implants (n = 3), or
two E2 silastic and three P4 elastomer implants (n = 3), based on preliminary dose response re-
sults. Silastic implants were prepared from silastic medical grade tubing (3.35 mm×4.65 mm
OD; 8 cm total length; Dow Corning, Midland, MI, USA) that were filled with E2 [20]. Sil-
icone elastomer implants (Sil-Estrus, Abbott Laboratories, North Chicago, IL, USA), each
containing 375 mg P4, were used to provide P4. Blood samples from ovariectomized ewes
were collected via jugular venipuncture prior to implant placement (day 0) and before hys-
terectomy on day 14. Blood samples were allowed to clot at 4◦C, and serum was collected
by centrifugation and stored at −20◦C until assayed for concentrations of P4 and E2. P4 was
assayed using a rabbit antiprogesterone-11-bovine serum albumin (Cambridge medical Tech-
nology, Billerica, MA, USA) in one assay [21]. Estradiol-17 was assayed using an antiserum
provided by N. R. Mason (Lilly Research Laboratories, Indianapolis, IN, USA) in one assay
[22]. On day 14 of implant treatment, group I ewes were anesthetized as previously described
and hysterectomy was performed. Group II ewes were monitored for estrus with vasectomized
rams fitted with marking harnesses, and estrus was recorded twice daily. Group III ewes were
monitored for estrus and mated by two fertile rams fitted with marking harnesses, and estrus
and mating were recorded twice daily. Hysterectomies were performed on group II ewes on
day 14 of the estrous cycle and on group III ewes on day 14 after mating.
2.2. Tissue culture
After hysterectomy, uteri were immediately placed on ice and uteri from all ewes were
transported to the laboratory and processed within 15 min. Uteri of pregnant ewes were flushed
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with 20–30 mL sterile phosphate-buffered saline (PBS, pH 7.2) to recover conceptuses. Con-
ceptuses were removed from the flushing media and protease inhibitor (PMSF, 1 mM) was
added to each uterine flush before freezing (liquid nitrogen) and storing at −80◦C for later
GM-CSF analysis by bioassay (described later). Endometrial tissue was stripped from the
uterus, minced, and an equal mass of tissue (300 mg wet weight, three culture dishes per ewe)
from each implant-treated ovariectomized, cyclic and pregnant ewe was cultured in 10 mL
Eagle’s minimum essential medium (Sigma Chemical Co., St. Louis, MO, USA). All samples
were cultured at 37◦C on a rocking platform under 50% N2, 45% O2, and 5% CO2. Following
a 24 h culture period, endometrium was collected by centrifugation at 2500 rpm for 5 min.
Culture medium was collected and stored at −20◦C, and cultured endometrial samples were
frozen in liquid nitrogen and stored at −80◦C until RNA extraction was performed.
2.3. Quantitation of GM-CSF mRNA
Total RNA was extracted from 300 mg of cultured endometrial tissue samples according
to the method of Chomzynski and Sacchi [23]. After spectrophotometric quantitation of
samples, integrity of extracted RNA was confirmed by the presence of distinct 18s and 28s
rRNA bands through an agarose gel electrophoresis containing ethidium bromide (2g/mL)
to visualize the RNA [24]. Relative levels of GM-CSF mRNA were quantitated by reverse
transcription–polymerase chain reaction (RT–PCR) method as described by Nephew et al.
[25]. Preliminary experiments were performed to validate the primer specificity and PCR con-
ditions under which each amplification reaction was confined to the exponential phase. For
the determination of primer specificity, endometrial RNA samples (5g each) from group I,
II and III ewes were treated with RNase free DNase (Stratagene, South San Francisco, CA,
USA) and then reverse transcribed with AMV reverse transcriptase (Promega, Madison, WI,
USA) in the presence of a 3′-downstream primer corresponding to bp 340–361 (5′-CTG GGT
TTC ACA GGA AGT TTC C-3′) [26]. The resulting cDNA was amplified through 30 cycles
(94:60:74◦C for 1, 1, and 2 min, respectively) of PCR using a 5′-upstream primer correspond-
ing to bp 14–33 (5′ATG TGG CTG CAG AAC CTG CT-3′). The amplification products were
electrophoresed on a 1.5% agarose gel containing ethidium bromide (10g/mL) to visualize
a 348 bp band. The PCR products were eluted from the agarose gel, cloned into pBS vector
(Stratagene, South San Francisco, CA, USA) and nucleotides were determined by dideoxy
sequencing method (Sequenase, Amersham Life Science, Cleveland, OH, USA) [27]. Nu-
cleotide sequences confirmed that these primers were specific for the detection of oGM-CSF
mRNA. For cRNA standard preparation, oGM-CSF cDNA (500 bp; C.J. McInnes, Moredun
Research Institute, Edinburgh, UK) was appropriately linearized and sense strand oGM-CSF
cRNA was produced by an in vitro transcription [24,25]. cRNA standards, ranging from 0.01
to 60 pg, were reverse transcribed using the 3′-downstream primer as aforementioned. Re-
sulting cDNAs were amplified with the upstream primer labeled with 32P--dATP (specific
activity 6000 Ci/mmol; Dupont NEN, Boston, MA, USA). PCR was carried out 20–25 cycles
to yield PCR products proportional to the initial concentrations of cRNA. Amplified products
were examined on an agarose gel and incorporated radioactivity was determined by liquid
scintillation counting [25,28,29]. Levels of cRNA standard were plotted against radioactivity
(cpm); data were also plotted against PCR cycle number, and a linear line was fitted to each
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curve [30]. RNA samples along with cRNA standards ranging from 0.1 to 30 pg were reverse
transcribed with the downstream primer. The resulting cDNA was amplified for 22 cycles us-
ing the upstream primer, which had been validated to be proportional to the range (0.1–30 pg)
of cRNA standard. Control reactions, RNA without reverse transcriptase and PCR without
cDNA template were run in parallel, which resulted in no PCR product. Levels of GM-CSF
mRNA for RNA samples were then calculated from the standard curve.
2.4. Bioassay of GM-CSF
After endometrial culture, whole medium samples (10 mL/culture) along with oGM-CSF
enriched conditioned media prepared from COS-1 monkey kidney cells (oGM-CSF CM, C.J.
McInnes) were dialyzed in the presence of protease inhibitors, pepstatin A (0.7 mg/mL) and
leupeptin-propionyl (0.35 mg/mL). A total of 500L endometrial culture media was used
for a bioassay and the remaining medium (9.5 mL) and oGM-CSF CM upon concentration
were subjected to western blot analysis. Concentrations of oGM-CSF in endometrial culture
and uterine flushing media were quantified by a proliferation bioassay using GM-CSF de-
pendent TF-1 cells [31] supplied by L. Guilbert (Department of Immunology, University of
Alberta, Alberta, Canada). TF-1 cells were grown in RPMI medium 1640 (Gibco BRL, Grand
Island, NY, USA) containing 10% fetal bovine serum (FBS) and 5 ng/mL human recom-
binant GM-CSF (hrGM-CSF; Genetics Institute, Cambridge, MA, USA). Before GM-CSF
assay, these cells were deprived of hrGM-CSF for 24 h. Four thousand TF-1 cells, prepared
in 50L RPMI 1640 medium, were added to hrGM-CSF standard (5, 10, 20, 40, 80, 160,
320, and 660 pg/mL), endometrial culture samples, and uterine flushing samples in tripli-
cate. The final volume (150L, which contained 10% FBS) was cultured at 37◦C under
the conditions of 95% air and 5% CO2 for 3 days. On day 4 of the culture, 5L RPMI
1640 containing 1Ci 3H-thymidine (specific activity 70–90 Ci/mmol; DuPont NEN, Boston,
MA, USA) and 10% FBS (Sigma Chemical Co., St. Louis, MO, USA) were added to each
well and incubated for 4 h. The cells were harvested in a cell-harvester fitted with filter pa-
per (DE81, Whatman International, Ltd., Maidstone, UK) to measure 3H-thymidine incor-
poration. A total of eight standards were placed at the beginning, middle, and end of each
plate. In order to assess assay variation, oGM-CSF CM and pooled endometrial culture me-
dia in triplicate were included in each assay. Assay sensitivity was 23 pg per well and the
intra and interassay coefficient of variation, calculated from the values of GM-CSF CM and
pooled samples within and between assays, were 6.2 and 9.1%, respectively. To determine
the specificity of the bioassay, an antibody against oGM-CSF (described later) was prepared
and used to neutralize hrGM-CSF, oGM-CSF CM and oGM-CSF from endometrial culture
media. More than 95% of GM-CSF, regardless of species, was neutralized with this azide-free
antiserum.
2.5. oGM-CSF antibody production and western blot analysis
An antibody to a synthetic peptide representing a portion of oGM-CSF was developed using
the following strategy: an antigenic site along the deduced amino acid sequence of oGM-CSF
[26] was determined by assigning each amino acid hydrophilicity values. The point of the
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highest local average hydrophilicity is invariably located in, or immediately adjacent to, an
antigenic determinant [32,33]. An antiserum to that domain prepared by Research Genetics
(Huntsville, AL, USA) is ETQIITFKSFKENLKD, which is equivalent to a region found in
hrGM-CSF [34].
After dialysis, 9.5 mL samples of endometrial culture media or 3 mL samples of oGM-CSF
CM were concentrated by Centricon (Amicon, Beverly, MA, USA), separated by 12.5%
SDS–PAGE and then electrotransferred to Immobilon (Millipore, Bedford, MA, USA) [6]. The
filters were blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween-20
(TBST). The filters were then incubated with rabbit preimmune serum or anti-oGM-CSF an-
tibody at a dilution of 1:1000 in TBST. The immunoreactive proteins were detected using
alkaline-phosphatase conjugated to rabbit IgG antibody.
2.6. In situ hybridization and immunohistochemistry
In addition to endometrial tissues subjected to in vitro culture study, a 0.125 cm3 (0.5 cm×
0.5 cm × 0.5 cm) section of uterus from all treatment groups was fixed, paraffin embedded,
sectioned and evaluated for the presence of GM-CSF mRNA and its protein. In situ hybridiza-
tion was performed as previously described [6,8]. Briefly, oGM-CSF cDNA (C.J. McInnes)
of which a portion of the 3′ region had been subcloned into pBS M13 [8,26], was appro-
priately linearized and sense and antisense GM-CSF cRNA probes were produced using T3
and T7 RNA polymerases, respectively. Digoxigenin-11 UTP (Boehringer Mannheim, Indi-
anapolis, IN, USA) was incorporated into the probes during in vitro transcription. Binding of
oGM-CSF cRNA to endometrial tissues was detected by antidigoxigenin antibody conjugated
with alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN, USA). Sections were then
counterstained with methyl green.
Immunohistochemistry was performed with the oGM-CSF antiserum described previously.
Briefly, a rabbit polyclonal antibody to the oGM-CSF oligopeptide was used at a dilution of
1:250 in PBS, and binding was detected by means of an avidin–biotin immunoperoxidase
staining kit [6]. 3-amino-9-ethylcarbazole in N,N-dimethylformamide (Zymed Laboratories,
Inc., South San Francisco, CA, USA) was used as substrate for the peroxidase, and positive cells
were identified by the presence of a reddish-brown reaction product. An equal concentration
of preimmune serum was used on semiserial sections of the same tissue to evaluate nonspecific
binding of the avidin–biotin immunoperoxidase. Tissue sections were then counterstained with
hematoxylin.
2.7. Statistical analysis
Data obtained from ovariectomized, cyclic and pregnant ewes were analyzed as a one-way
analysis of variance [30] of six treatment groups (i.e., ovariectomized control (1), ovariec-
tomized plus E2 implant (2), ovariectomized plus P4 implant (3), ovariectomized plus E2 and
P4 implants (4), cyclic (5), and pregnant (6)). The sums of squares were partitioned into sin-
gle degree of freedom contrasts ((1) versus (2), (1) versus (3), (1) versus (4), (4) versus (5),
(5) versus (6), and (4) versus (6)) that had been selected a priori to compare the treatment
groups.
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Table 1
Serum concentrations of E2 and P4 before and after E2 and/or P4 treatment in group I ovariectomized ewes
Treatment E2 (pg/mL) P4 (ng/mL)
Day 0a Day 14a Day 0a Day 14a
Control 4.6 ± 0.4 6.4 ± 1.5 0.04 ± 0.01 0.21 ± 0.15
E2 5.7 ± 1.0 40.5 ± 6.2 0.07 ± 0.02 0.08 ± 0.03
P4 4.1 ± 0.3 5.4 ± 0.24 0.07 ± 0.04 2.27 ± 0.31
E2/P4 6.2 ± 0.9 46.4 ± 10.3 0.09 ± 0.01 1.51 ± 0.52
Mean ± SEM.
a Blood samples were collected before implanting ewes on day 0 and before hysterectomy on day 14.
Fig. 1. Mean (±SEM) levels of GM-CSF mRNA in cultured endometrium from group I, II and III ewes. RNA was
isolated from cultured endometrium and subjected to quantitative RT–PCR. (A) Depicts group I, ovariectomized
ewes assigned to the following treatments: controls, E2, P4 and E2/P4. (B) Depicts group I (E2/P4), group II (day
14 cyclic) and group III (day 14 pregnant) ewes. (∗) Indicates that the mean is different from control (P < 0.05).
Means having different superscripts (x, y) differ (P < 0.01).
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3. Results
Mean serum concentrations of E2 and P4 in group I ovariectomized ewes, as determined by
specific RIA on days 0 and 14, are shown in Table 1. Serum concentrations of E2 and P4 did
not differ between day 0 and 14 in ovariectomized ewes that did not receive E2 or P4 implants.
Serum concentrations of E2 in the E2- and E2/P4-treated ovariectomized ewes on day 14 were
40.5 ± 6.2 and 46.4 ± 10.3 pg/mL, respectively. Similarly, serum concentrations of P4 in the
P4- and E2/P4-treated ewes on day 14 were 2.27± 0.31 and 1.51± 0.52 ng/mL, respectively.
After RT–PCR of GM-CSF cRNA standards (0.1–30 pg), levels of cRNA were plotted
versus cpm producing a linear standard curve with an r2 of 0.993 (y = −7091.7+ 1.6876x).
The incorporated cpm (3000–65,000 cpm) resulting from RT–PCR of RNA samples yielded
values that fell within the standard curve (0.1–30 pg). Levels of GM-CSF mRNA extracted from
cultured endometrial tissues obtained from E2- and E2/P4-treated ovariectomized ewes were
Fig. 2. Mean (±SEM) concentrations of bioactive GM-CSF in medium from cultured endometrium from group I,
II and III ewes. GM-CSF was determined by bioassay based on proliferation of GM-CSF dependent TF-1 cells.
(A) Depicts group I, ovariectomized ewes assigned to the following treatments: control, E2, P4 and E2/P4. (B)
Depicts group I (E2/P4), group II (day 14 cyclic) and group III (day 14 pregnant) ewes. (∗) Indicates that the mean
is different from control (P < 0.01). Means having different superscripts (x, y) differ (P < 0.01).
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higher (P < 0.05) than those seen in controls (Fig. 1A). GM-CSF mRNA levels extracted
from cultured endometrial tissues from P4-treated ovariectomized ewes were not different
from controls. GM-CSF mRNA levels from cultured endometrial tissues from E2/P4-treated
ovariectomized and cyclic ewes were less (P < 0.01) than that of pregnant ewes (Fig. 1B).
GM-CSF concentrations, determined by a bioassay, in endometrial culture media obtained
from either E2- or P4-treated ovariectomized ewes were not different from those seen in controls
(Fig. 2A). The combined treatment of E2/P4 resulted in a 3-fold increase (P < 0.01) in
GM-CSF secreted into culture media as compared to that of control ovariectomized ewes.
However, GM-CSF concentrations in endometrial culture media obtained from E2/P4-treated
ovariectomized and cyclic ewes were similar and both of these were less (P < 0.01) than that of
pregnant ewes (Fig. 2B). In addition, GM-CSF detected in the uterine flushing media (23 mL)
obtained from pregnant ewes was 86 ± 21 pg/mL, resulting in approximately 2 ± 0.5 ng in
utero at the time of hysterectomy.
Results of GM-CSF western blot analysis are presented in Fig. 3. The anti-oGM-CSF an-
tibody detected a band approximately 23 kDa in size in endometrial culture medium, which
is in agreement with the value for mouse native GM-CSF reported in a previous study [7].
Immunoreactive GM-CSF was detected in samples of endometrial culture media from the
E2/P4-treated ovariectomized, cyclic and pregnant ewes and not in endometrial culture media
from control, E2- or P4-treated ovariectomized ewes.
Fig. 3. Western blot analysis of GM-CSF released into culture medium from endometrium of ovariectomized, cyclic
and pregnant ewes. Endometrial culture media (9.5 mL) and oGM-CSF enriched conditioned media (oGM-CSF
CM) were dialyzed, concentrated, separated by 12.5% SDS–PAGE and transferred to filters. Filters were incubated
with rabbit preimmune serum or anti-oGM-CSF antiserum, and immunoreactive proteins detected by alkaline
phosphatase conjugated to rabbit IgG antibody. Lane (1) Mr markers, (2) oGM-CSF CM with preimmune serum, (3)
oGM-CSF CM with the anti-oGM-CSF antiserum, (4) control-ovariectomized ewe, (5) E2-treated ovariectomized
ewe, (6) P4-treated ovariectomized ewe, (7) E2/P4-treated ovariectomized ewe, (8) day 14 cyclic ewe, and (9) day
14 pregnant ewe.
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Fig. 4. Localization of oGM-CSF mRNA and its protein to uterine endometria from ovariectomized, cyclic, and
pregnant ewes. Bar = 100m; all micrographs are same magnification. Cellular localization of oGM-CSF mRNA
by: (A) oGM-CSF sense cRNA probe to semiserial section from day 14 pregnant ewe (no hybridization), (B)
oGM-CSF antisense cRNA probe to section from E2-treated ovariectomized ewe (hybridization), (C) oGM-CSF
antisense cRNA probe to section from P4-treated ovariectomized ewe (no hybridization), (D) oGM-CSF antisense
cRNA probe to section from E2/P4-treated ovariectomized ewe (hybridization), (E) oGM-CSF antisense cRNA
probe to section from a day 14 cyclic ewe (hybridization), (F) oGM-CSF antisense cRNA probe to semiserial
section (see (A)) from a day 14 pregnant ewe (hybridization). Because no hybridization was observed, endometrial
section from control-ovariectomized ewe are not shown. Immunohistochemical localization of oGM-CSF by:
(G) preimmune rabbit serum (negative control) to semiserial section from day 14 pregnant ewe (no staining), (H)
anti-oGM-CSF antiserum to section from E2-treated ovariectomized ewe (no staining), (I) anti-oGM-CSF antiserum
to section from E2/P4-treated ovariectomized ewe (staining), (J) anti-oGM-CSF antiserum to semiserial section (see
(G)) from day 14 pregnant ewe (staining). Because no staining was observed, endometrial sections from control or
P4-treated ovariectomized ewe are not shown.
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Results of in situ hybridization and immunohistochemical analyses for GM-CSF are pre-
sented in Fig. 4. Results from in situ hybridization studies agreed with GM-CSF mRNA levels
detected by RT–PCR (Fig. 1), with the positive staining being observed in sections of uteri
obtained from pregnant, cyclic and E2- and E2/P4-treated ovariectomized animals. Similar to
the previous results [8], GM-CSF mRNA was localized to the luminal and glandular epithelial
and stromal regions. Minimal to nondetectable staining was observed in tissues obtained from
the control and P4-treated ovariectomized ewes.
GM-CSF protein was detected at the luminal and glandular epithelia in endometrial sections
obtained from ewes in the E2/P4-treated ovariectomized, cyclic, and pregnant animals (Fig. 4).
No staining was associated with the luminal and glandular epithelia of endometrial tissues from
the control or P4-treated ovariectomized ewes. However, minor staining of GM-CSF was noted
at the edge of luminal epithelium in one of three E2-treated ovariectomized animals while no
staining was observed in the endometrium of the remaining E2-treated ovariectomized ewes.
These results were in close agreement with the results of the bioassay (Fig. 2) and western blot
analysis (Fig. 3), which indicated that GM-CSF protein was present in appreciable quantities
in the E2/P4-treated ovariectomized, cyclic and pregnant ewes.
4. Discussion
In ovariectomized ewes, the implants produced serum concentrations of P4 that mimicked
those seen in vivo during the late luteal phase or early pregnancy in ewes [35]. Concentra-
tions of E2 in serum of ovariectomized ewes with E2 implants were higher than previously
reported. However, the magnitude of increase in serum concentrations of E2 produced by the
E2 implants was similar to that shown by Karsch et al. [20] and Goodman et al. [35]. The
steroid environment produced by the implants was maintained for 14 days, which should have
adequately allowed for any necessary steroid priming of the endometrium. It should be noted
that by pathological examination, the E2/P4 regimen utilized in this study were not found to
cause uterine edema or to alter the cellular composition of the uterus (I. Damjanov, Univer-
sity of Kansas Medical Center, Kansas City, KS, USA). Therefore, GM-CSF expression in
E2- or E2/P4-treated ovariectomized ewes observed in the present study did not result from
pharmacological or confounding effects of E2.
Treatment of ovariectomized ewes with E2 implants stimulated increases in levels of endome-
trial GM-CSF mRNA, presumably through increased transcription and/or message stability
[36]. Although P4 diminishes GM-CSF mRNA synthesis in the mouse [16], P4 treatment alone,
when implanted for 14 days in sheep, did not stimulate or inhibit endometrial GM-CSF mRNA
or protein levels. Although GM-CSF mRNA levels were elevated in endometrium obtained
from E2-treated ewes, no additional increase in GM-CSF protein was detected in these ani-
mals and, therefore, GM-CSF protein levels remained similar to controls. P4 treatment along
with E2 in the ovariectomized ewes increased GM-CSF protein to the level detected in cyclic
ewes. However, the degree of GM-CSF expression in E2/P4-treated ovariectomized and cyclic
ewes was still less than that of pregnant animals. These data suggest that the combined E2 and
P4 treatment of ovariectomized ewes sufficiently restores GM-CSF expression to the level of
cyclic ewes and that the conceptus may play a role in the regulation of GM-CSF expression in
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utero. Higher GM-CSF levels detected in pregnant animals agree with the recent observations
in which oIFN enhanced endometrial GM-CSF [37]. Additionally, detection of GM-CSF
protein in the uterine flushing indicates that bioactive protein, at least by the bioassay of the
TF-1 cells, is present in utero. The fact that GM-CSF is not detected in the ovine conceptuses
[6] further confirms that the source of GM-CSF production is the uterine endometrium. The
present study also confirms the results by Giacomini et al. [15] and Robertson et al. [16] in
which GM-CSF expression in utero occurs at the luminal and glandular epithelial cells, not
by lymphocytes recruited by the endometrium.
These results indicate that the steroidogenic environment of early pregnancy should be capa-
ble of inducing the expression of endometrial GM-CSF, which in turn has been demonstrated
to increase oIFN production from the ovine conceptus [6,8]. The molecular mechanism(s)
by which the conceptus upregulates endometrial expression of GM-CSF during early concep-
tus development is still unclear. However, oIFN could be a factor that enhances endometrial
GM-CSF production [37]. To study the effect of conceptus and/or conceptus secretory pro-
tein(s) on endometrial production of GM-CSF is beyond the scope of the present investigation.
However, this localized production of bioactive GM-CSF that is readily available to the concep-
tus provides further evidence for the existence of a biochemical network of embryo-maternal
communication.
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